Fernández-Lázaro Diego, Ortega Carlos Domínguez, Sánchez-Serrano Nerea, Beddar Chaib Fahd, Jerves Donoso David, Jiménez-Callejo Elena, Rodríguez-García Saray
Department of Cellular Biology, Histology and Pharmacology, Faculty of Health Sciences, University of Valladolid, Campus of Soria, 42003 Soria, Spain.
Neurobiology Research Group, Faculty of Medicine, University of Valladolid, 47005 Valladolid, Spain.
Pharmaceutics. 2022 May 9;14(5):1020. doi: 10.3390/pharmaceutics14051020.
Coronavirus 2019 disease (COVID-19) represents one of the largest pandemics the world has faced, and it is producing a global health crisis. To date, the availability of drugs to treat COVID-19 infections remains limited to supportive care although therapeutic options are being explored. Some of them are old strategies for treating infectious diseases. convalescent plasma (CP) therapy has been used successfully in other viral outbreaks in the 20th century. In this study, we systematically evaluated the effect and safety of CP therapy on hospitalized COVID-19 patients. A structured search was conducted following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines using Medline (PubMed), SciELO, Cochrane Library Plus, Web of Science, and Scopus. The search included articles published up to January 2022 and was restricted to English- and Spanish-language publications. As such, investigators identified six randomized controlled trials that met the search criteria. The results determined that in hospitalized COVID-19 patients the administration of CP therapy with a volume between 200-500 mL and a single transfusion performed in 1-2 h, compared to the control group, decreased viral load, symptomatology, the period of infection, and mortality, without serious adverse effects. CP did influence clinical outcomes and may be a possible treatment option, although further studies will be necessary.
2019冠状病毒病（COVID-19）是全球面临的最大规模的大流行疾病之一，正在引发一场全球健康危机。迄今为止，尽管正在探索治疗方案，但用于治疗COVID-19感染的药物仍然仅限于支持性治疗。其中一些是治疗传染病的旧策略。恢复期血浆（CP）疗法在20世纪的其他病毒爆发中已成功应用。在本研究中，我们系统地评估了CP疗法对住院COVID-19患者的疗效和安全性。按照系统评价和Meta分析的首选报告项目（PRISMA）指南，使用Medline（PubMed）、SciELO、Cochrane Library Plus、Web of Science和Scopus进行了结构化检索。检索包括截至2022年1月发表的文章，并仅限于英文和西班牙文出版物。因此，研究人员确定了六项符合检索标准的随机对照试验。结果表明，与对照组相比，在住院的COVID-19患者中，输注200-500mL的CP疗法并在1-2小时内进行单次输血，可降低病毒载量、症状、感染期和死亡率，且无严重不良反应。CP确实影响临床结局，可能是一种可行的治疗选择，尽管还需要进一步研究。
